Universidade Estadual de Campinas (UNICAMP) - Laboratory of Urogenital Carcinogenesis and Immunotherapy
Date Written: May 24, 2020
Abstract
A 78-year old male patient under active immunotherapy for high-grade non-muscle invasive bladder cancer presented severe COVID-19. A shorter hospitalization period was observed, leading to the hypothesis of active immunotherapy (OncoTherad) crucial role in association to antiviral and anti-inflammatory treatment in preventing the evolution of pulmonary symptoms to a poor prognosis.
Note: Funding: This work was supported by São Paulo Research Foundation (FAPESP) [2019/05718-3 to J.D. and 2018/10052-1 to W.J.F].
Conflict of Interest: The authors declare no competing interests.
Ethical Approval: This study was approved by the ethics committee at UNICAMP.
Delafiori, Jeany and Alonso, João Carlos Cardoso and Santos, Luiz Augusto dos and Oliveira, Diogo Noin de and Navarro, Luiz Cláudio and Busanello, Estela Natacha Brandt and Sales, Geovana Manzan and Oliveira, Arthur Noin de and Rocha, Anderson Rezende and Durán, Nelson and Catharino, Rodrigo Ramos and Favaro, Wagner, A 78-Year Old Urothelial Cancer Patient with Faster Recovery from COVID-19: Potential Benefit from Adjuvant Active Immunotherapy (May 24, 2020). Available at SSRN: https://ssrn.com/abstract=3609259 or http://dx.doi.org/10.2139/ssrn.3609259
Subscribe to this fee journal for more curated articles on this topic
FOLLOWERS
59
PAPERS
542
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.
Download This Paper